+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cellectis Inc - logo

Cellectis is a gene-editing company that develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company designs novel products including immune therapies for cancer and enzymes which can add DNA at targeted places in genomes. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies which develop in acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia. Cellectis S.A. was founded in 1999 and is based in Paris, France.

CRISPR Technology: Global Markets - Product Thumbnail Image

CRISPR Technology: Global Markets

  • Report
  • May 2020
  • 83 Pages
From
From
Global DNA Read, Write and Edit Market - Product Thumbnail Image

Global DNA Read, Write and Edit Market

  • Report
  • September 2019
  • 399 Pages
From
North America CRISPR Market 2021-2028 - Product Thumbnail Image

North America CRISPR Market 2021-2028

  • Report
  • September 2021
  • 144 Pages
From
Latin America CRISPR Market 2021-2028 - Product Thumbnail Image

Latin America CRISPR Market 2021-2028

  • Report
  • September 2021
  • 126 Pages
From
Global CRISPR Market 2021-2028 - Product Thumbnail Image

Global CRISPR Market 2021-2028

  • Report
  • September 2021
  • 245 Pages
From
Europe CRISPR Market 2021-2028 - Product Thumbnail Image

Europe CRISPR Market 2021-2028

  • Report
  • September 2021
  • 156 Pages
From
Asia-Pacific CRISPR Market 2021-2028 - Product Thumbnail Image

Asia-Pacific CRISPR Market 2021-2028

  • Report
  • September 2021
  • 153 Pages
From
Middle East and Africa CRISPR Market 2021-2028 - Product Thumbnail Image

Middle East and Africa CRISPR Market 2021-2028

  • Report
  • September 2021
  • 112 Pages
From
From
From
From
From
From
From
CAR T-cell Therapy - Pipeline Insight, 2022 - Product Thumbnail Image

CAR T-cell Therapy - Pipeline Insight, 2022

  • Clinical Trials
  • January 2022
  • 60 Pages
From
Loading Indicator